NCT01951599 - To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2013

Primary Completion Date

June 4, 2014

Study Completion Date

June 4, 2014

Conditions

Healthy Volunteers

Interventions

DRUG

AZD9291

Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).

DRUG

AZD9291

Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).

DRUG

AZD9291

Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).

DRUG

AZD9291

Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.

DRUG

AZD9291

Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.

Trial Locations (1)

Research Site, Overland Park